These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 21067252

  • 1. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study.
    Gobin J, Cernii A, McLean R, Finkelstein FO, Simon DB.
    Clin Drug Investig; 2011; 31(2):113-20. PubMed ID: 21067252
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.
    Kuwahara M, Hasumi S, Mandai S, Tanaka T, Shikuma S, Akita W, Mori Y, Sasaki S.
    Clin Exp Nephrol; 2014 Oct; 18(5):755-62. PubMed ID: 24317507
    [Abstract] [Full Text] [Related]

  • 4. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
    Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF.
    Cochrane Database Syst Rev; 2014 Dec 08; 2014(12):CD010590. PubMed ID: 25486075
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH, Tarng DC, Lee KF, Wu CY, Chen YC.
    J Nephrol; 2008 Dec 08; 21(4):543-9. PubMed ID: 18651544
    [Abstract] [Full Text] [Related]

  • 10. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.
    Silver MR, Agarwal A, Krause M, Lei L, Stehman-Breen C.
    Am J Geriatr Pharmacother; 2008 Jun 08; 6(2):49-60. PubMed ID: 18675764
    [Abstract] [Full Text] [Related]

  • 11. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
    Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, Beyer U, STRIATA Study Investigators.
    Nephrol Dial Transplant; 2008 Nov 08; 23(11):3654-61. PubMed ID: 18586762
    [Abstract] [Full Text] [Related]

  • 12. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
    Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF.
    Cochrane Database Syst Rev; 2017 Aug 07; 8(8):CD009904. PubMed ID: 28782299
    [Abstract] [Full Text] [Related]

  • 13. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
    Biggar P, Ketteler M, Hennemann H, Dömling R.
    Clin Nephrol; 2008 Mar 07; 69(3):185-92. PubMed ID: 18397717
    [Abstract] [Full Text] [Related]

  • 14. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R.
    Clin Ther; 2003 Nov 07; 25(11):2781-96. PubMed ID: 14693304
    [Abstract] [Full Text] [Related]

  • 15. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease.
    Hudson JQ, Sameri RM.
    Pharmacotherapy; 2002 Sep 07; 22(9 Pt 2):141S-149S. PubMed ID: 12222584
    [Abstract] [Full Text] [Related]

  • 16. Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.
    Krause MW, Raja R, Agarwal A, Silver MR, Scarlata D, Sciarra A, Kewalramani R.
    Drugs Aging; 2009 Sep 07; 26(8):665-75. PubMed ID: 19685932
    [Abstract] [Full Text] [Related]

  • 17. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
    Grabe DW.
    Am J Health Syst Pharm; 2007 Jul 01; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
    [Abstract] [Full Text] [Related]

  • 18. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Siegel J, Jorgenson J, Johnson PE, Brophy DF, Comstock T, Feng A, Audhya P.
    Am J Health Syst Pharm; 2008 Sep 15; 65(18):1711-9. PubMed ID: 18768997
    [Abstract] [Full Text] [Related]

  • 19. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.
    Curr Med Res Opin; 2006 Oct 15; 22(10):2023-30. PubMed ID: 17022861
    [Abstract] [Full Text] [Related]

  • 20. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.
    Pharmacoeconomics; 2006 Oct 15; 24(5):479-94. PubMed ID: 16706573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.